How to appeal a Highmark c. difficile infection denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Highmark-specific note: Operates BCBS in PA (western), WV, DE, NY (western). Owns Allegheny Health Network.

What Highmark's policy requires for c. difficile infection

Cited policy: BCBS Medical Policy on Vowst (Fecal Microbiota Spores, live-brpk)

Adult ≥18 yr. ≥1 CDI recurrence following completion of antibiotic treatment for prior episode. 4 capsules PO daily x 3 consecutive days, starting 2-4 days after final antibiotic dose. Not for treatment of active CDI.

How Highmark denies c. difficile infection — and how to counter it

Where Highmark pushes back: 1) Experimental / investigational; 2) Step therapy: try Rebyota first; 3) Reserved for multiply recurrent (≥3 episodes); 4) Long-term data insufficient.

Counter-arguments that hold up: Vowst was FDA-APPROVED on April 26, 2023 — the FIRST oral FDA-approved live microbiota therapeutic. Indication (per FDA label): prevention of recurrence of CDI in adults following antibacterial treatment for recurrent CDI (i.e., ≥1 prior recurrence — 2nd episode onward). Approval based on ECOSPOR III (Feuerstadt NEJM 2022;386(3):220-229) — 88% recurrence-free at 8 wk vs 60% placebo; 79% vs 53% at 6 mo. ECOSPOR IV open-label confirmatory data also in FDA dossier. AGA Living Guideline 2024 supports Vowst and Rebyota as parallel options based on patient preference (oral vs rectal) — no step-therapy hierarchy mandated. ACG 2021 endorses microbiota-based therapy after recurrent CDI.

What Highmark typically denies for c. difficile infection

Across Highmark's commercial and Medicare books, denials cluster around a small number of patterns. For c. difficile infection, expect:

• Prior auth on biologics
• PA on advanced imaging
• OON balance bills

Treatments most often denied in this category

These are the c. difficile infection treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Fidaxomicin (Dificid)
• Fidaxomicin extended-pulsed
• Vancomycin PO
• Vancomycin enema
• Bezlotoxumab (Zinplava)
• Rebyota

How to submit the appeal to Highmark

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Highmark cited in the denial.
3. File the appeal through Highmark's portal (members: https://www.highmark.com ; providers: https://www.highmark.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In PA, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Highmark's prior-authorization criteria by drug: Highmark PA criteria on ApprovalHelp.